The molecular programme of tumour reversion: the steps beyond malignant transformation

Telerman, Adam; Amson, Robert

doi:10.1038/nrc2589

Cited by 169 publications

(157 citation statements)

References 142 publications

Supporting

Mentioning

150

Contrasting

Unclassified

Order By: Relevance

“…Instrumental in this was the experimental 'tumour reversion model' developed by the Telerman group (Telerman and Amson 2009;Tuynder et al 2002Tuynder et al , 2004. Naturally, the cancer aspect of TCTP's 'function' has recently attracted increasing attention, as documented by the about 40 papers and 6 review articles (Telerman and Amson 2009;Bommer 2012;Acunzo et al 2014;Amson et al 2013Amson et al , 2011Chan et al 2012a;Efferth 2006;Koziol and Gurdon 2012) on 'TCTP and cancer' that appeared only within the last 10 years.…”

Section: The 'Translationally Controlled Tumour Protein Tctp': Names mentioning

confidence: 99%

“…Last but not least, the frequent reports on TCTP overexpression in cancer cells and human tumours (reviewed in Bommer 2012; Acunzo et al 2014;Chan et al 2012a;Koziol and Gurdon 2012) and on its down-regulation in the tumour reversion model (Telerman and Amson 2009;Amson et al 2013) provide additional compelling evidence that TCTP is a growth-promoting protein. These aspects are discussed below, in Sect.…”

Section: Tctp and Cell Growth Regulationmentioning

confidence: 99%

“…However, since the beginning of this century, a substantial body of evidence has been accumulated, demonstrating that TCTP is indeed overexpressed in cancer cells and in human tumours. A number of review articles have summarised these efforts (Telerman and Amson 2009;Bommer 2012;Acunzo et al 2014;Amson et al 2013;Chan et al 2012a;Koziol and Gurdon 2012), and the reader is referred to these for papers reporting overexpression of TCTP in cancer cell lines. Kaarbo et al (2013) those papers, which have dealt specifically with one specific type of cancer.…”

Section: Overexpression Of Tctp In Human Tumoursmentioning

confidence: 99%

“…This approach investigates the rare events of tumour cells reverting back from the malignant to the normal phenotype (Telerman and Amson 2009). The group showed that TCTP is one of the important proteins, whose expression is down-regulated in this process.…”

Section: Mechanistic Involvement In Cancer Progressionmentioning

confidence: 99%

“…This reflects the fact that by now, many functional aspects of this protein have been revealed, many of which are highly relevant to core biological and medical problems. The recent increasing interest in this protein is also reflected by the fact that 15 review articles on TCTP have already been published, all but two (Bommer and Thiele 2004;Telerman and Amson 2009) within the last 5 years. However, most of these articles focus on specific aspects of the TCTP literature, and they are spread over a wide range of journals.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

The Translational Controlled Tumour Protein TCTP: Biological Functions and Regulation

Bommer

2017

Results and Problems in Cell Differentiation

View full text Add to dashboard Cite

The Translational Controlled Tumour Protein TCTP (gene symbol TPT1, also called P21, P23, Q23, fortilin or histamine-releasing factor, HRF) is a highly conserved protein present in essentially all eukaryotic organisms and involved in many fundamental cell biological and disease processes. It was first discovered about 35 years ago, and it took an extended period of time for its multiple functions to be revealed, and even today we do not yet fully understand all the details. Having witnessed most of this history, in this chapter, I give a brief overview and review the current knowledge on the structure, biological functions, disease involvements and cellular regulation of this protein. TCTP is able to interact with a large number of other proteins and is therefore involved in many core cell biological processes, predominantly in the response to cellular stresses, such as oxidative stress, heat shock, genotoxic stress, imbalance of ion metabolism as well as other conditions. Mechanistically, TCTP acts as an anti-apoptotic protein, and it is involved in DNA-damage repair and in cellular autophagy. Thus, broadly speaking, TCTP can be considered a cytoprotective protein. In addition, TCTP facilitates cell division through stabilising the mitotic spindle and cell growth through modulating growth signalling pathways and through its interaction with the proteosynthetic machinery of the cell. Due to its activities, both as an anti-apoptotic protein and in promoting cell growth and division, TCTP is also essential in the early development of both animals and plants. Apart from its involvement in various biological processes at the cellular level, TCTP can also act as an extracellular protein and as such has been involved in modulating whole-body defence processes, namely in the mammalian immune system. Extracellular TCTP, typically in its dimerised form, is able to induce the release of cytokines and other signalling molecules from various types of immune cells. There are also several examples, where TCTP was shown to be involved in antiviral/antibacterial defence in lower animals. In plants, the protein appears to have a protective effect against phytotoxic stresses, such as flooding, draught, too high or low temperature, salt stress or exposure to heavy metals. The finding for the latter stress condition is corroborated by earlier reports that TCTP levels are considerably up-regulated upon exposure of earthworms to high levels of heavy metals. Given the involvement of TCTP in many biological processes aimed at maintaining cellular or whole-body homeostasis, it is not surprising that dysregulation of TCTP levels may promote a range of disease processes, foremost cancer. Indeed a large body of evidence now supports a role of TCTP in at least the most predominant types of human cancers. Typically, this can be ascribed to both the anti-apoptotic activity of the protein and to its function in promoting cell growth and division. However, TCTP also appears to be involved in the later stages of cancer progression, such ...

show abstract

Section: The 'Translationally Controlled Tumour Protein Tctp': Names mentioning

confidence: 99%

Section: Tctp and Cell Growth Regulationmentioning

confidence: 99%

Section: Overexpression Of Tctp In Human Tumoursmentioning

confidence: 99%

Section: Mechanistic Involvement In Cancer Progressionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

The Translational Controlled Tumour Protein TCTP: Biological Functions and Regulation

Bommer

2017

Results and Problems in Cell Differentiation

View full text Add to dashboard Cite

show abstract

New hydrazide derivatives of N‐amino‐11‐azaartemisinin as promising epidermal growth factor receptor inhibitors for therapeutic development in triple‐negative breast cancer

Karnatak,

Yadav,

Rathi

et al. 2024

Archiv der Pharmazie

View full text Add to dashboard Cite

Triple‐negative breast cancer (TNBC) treatments, such as DNA‐damaging agents like carboplatin, pose considerable human toxicity and may contribute to cancer relapse. Artemisinin derivatives offer a less toxic alternative; however, their specific role in TNBC management remains to be established. To address this gap, computational models were employed to design and evaluate artemisinin‐based prototypes as potential TNBC therapeutics, aiming to provide safer and more effective treatment options for this aggressive cancer subtype. Among the series of hydrazide derivatives of azaartemisinin (10a–l) reported herein, compound 10j emerged as the most promising, exhibiting notable cytotoxicity with IC50 values of 1.74 and 1.64 µM against MDA‐MB‐231 and MDA‐MB‐468 cells, respectively. The clinically useful drug doxorubicin provided IC50 values of 0.29 and 0.29 µM against MDA‐MB‐231 and MDA‐MB‐468 cells, while artemisinin provided IC50 values of 107.30 and 116.60 µM, respectively. Furthermore, putative interactions between the synthesized compounds and the epidermal growth factor receptor (EGFR) were identified using molecular docking studies, suggesting a possible mechanism for their anticancer effect. Additionally, to determine the thermodynamic parameters of the interactions between artemisinin, azaartemisinin, and biomolecules, isothermal titration calorimetry experiments were performed. The binding constant value on the order of 104 indicates a comparatively stronger binding affinity of azaartemisinin with human serum albumin (HSA) compared to artemisinin with HSA. These findings support the potential of azaartemisinin derivatives as promising EGFR inhibitors for therapeutic development in TNBC, offering a new avenue for less toxic and more effective cancer treatments.

show abstract

Revisiting the Molecular Interactions between the Tumor Protein TCTP and the Drugs Sertraline/Thioridazine

et al. 2021

View full text Add to dashboard Cite

show abstract

The molecular programme of tumour reversion: the steps beyond malignant transformation

Cited by 169 publications

References 142 publications

The Translational Controlled Tumour Protein TCTP: Biological Functions and Regulation

The Translational Controlled Tumour Protein TCTP: Biological Functions and Regulation

New hydrazide derivatives of N‐amino‐11‐azaartemisinin as promising epidermal growth factor receptor inhibitors for therapeutic development in triple‐negative breast cancer

Revisiting the Molecular Interactions between the Tumor Protein TCTP and the Drugs Sertraline/Thioridazine

Contact Info

Product

Resources

About